Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome — Stella

Recruiting

Back to Post-acute COVID-19 Syndrome trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

United States

Vanderbilt University Medical Center, Nashville, Tennessee

Key details

Sponsor

Vanderbilt University Medical Center

Collaborators

American Heart Association

Enrollment target

~60 participants

Started

June 2022

Primary completion

June 2026

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov